Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients

Running title: Impact of voriconazole resistant invasive aspergillosis

Agustin RESENDIZ-SHARPE ^{ϕ 1}, Toine MERCIER ^{ϕ 1,2}, Pieter P.A. LESTRADE ³, Martha T VAN DER BEEK⁴, Peter A. VON DEM BORNE ⁵, Jan J. CORNELISSEN ⁶, Elizabeth DE KORT ⁷, Bart J.A. RIJNDERS⁸, Alexander SCHAUWVLIEGHE ⁸, Paul E. VERWEIJ ⁹, Johan MAERTENS ^{1,2}, Katrien LAGROU ^{* 1,10}. On behalf of the Dutch-Belgian Mycosis study group.

Shared first authorship (ϕ)

Affiliations:

¹ Laboratory of Clinical Bacteriology and Mycology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

² Department of Haematology, University Hospitals Leuven, Leuven, Belgium.

³ Department of Medical Microbiology, Viecuri Medical Centre, Venlo, The Netherlands.

⁴ Department of Medical Microbiology, Leiden University Medical Centre, Leiden, The Netherlands.

⁵ Department of Haematology, Leiden University Medical Centre, Leiden, The Netherlands.

⁶ Department of Haematology, Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands.

⁷ Department of Haematology, Radboud University Medical Centre, Nijmegen, The Netherlands.

⁸ Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands.

⁹ Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; Centre of Expertise in Mycology, Radboud UMC/CWZ, Nijmegen, Netherlands.

¹⁰ Department of Laboratory Medicine and National Reference Center for Mycosis, Excellence Centre for Medical Mycology (ECMM), University Hospitals Leuven, Leuven, Belgium.

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

(*) Corresponding author:

Prof. Dr. Katrien LAGROU.

Laboratory of Clinical Bacteriology and Mycology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Department of Laboratory Medicine and National Reference Center for Mycosis, Excellence Centre for Medical Mycology (ECMM), University Hospitals Leuven, Leuven, Belgium.

Address: UZ Herestraat 49 - box 6711, 3000 Leuven, Belgium.

Telephone: +32 016 34 70 98

Fax: +32 016 34 79 31

E-mail: katrien.lagrou@uzleuven.be

Abstract

Objectives: Increasing resistance of *Aspergillus fumigatus* to triazoles in high-risk populations is a concern. Its impact on mortality is not well known but rates between 50% to 100% have been reported. In this study, we aim to determine the prevalence of voriconazole-resistant *A. fumigatus* invasive aspergillosis (IA) and its associated mortality in a large multicentre cohort of haematology patients with culture-positive IA.

Methods: We performed a multicentre-retrospective study, in which outcomes of culture-positive haematology patients with proven/probable IA were analysed. Patients were stratified based on the voriconazole susceptibility of their isolates (EUCAST broth microdilution test). Mycological, and clinical data were compared together with survival at 6 and 12 weeks.

Results: We identified 129 *A. fumigatus* culture-positive proven or probable IA cases, 103 voriconazole-susceptible (79.8%) and 26 voriconazole-resistant cases (20.2%). All but one resistant case harboured environment-associated resistance mutations in the *Cyp51A* gene: TR₃₄/L98H (13 cases) and TR₄₆/Y121F/T289A (12 cases). Triazole monotherapy was started in 75% (97/129) of patients. Mortality at 6 and 12 weeks was higher in voriconazole-resistant cases in all (42.3% versus 28.2%, $p=0.20$; and 57.7% versus 36.9%, $p=0.064$), and in non-ICU patients (36.4% versus 21.6%, $p=0.16$; and 54.4% versus 30.7%; $p=0.035$), compared to susceptible ones. ICU patients mortality was very high regardless of triazole susceptibility (75% versus 66.7%, $p=0.99$; and 75% versus 73.3%, $p=0.99$).

Conclusions: A very high prevalence of voriconazole resistance among culture-positive IA haematology patients was observed. The overall mortality at 12 weeks was significantly higher in non-ICU patients with voriconazole-resistant IA compared with voriconazole-susceptible IA.

Introduction

Invasive aspergillosis (IA) due to *Aspergillus fumigatus* is a common infectious complication among haematology patients.¹ Case-fatality rates of IA in these patients have decreased over the last years, from 68% (1995-1999),² to 32-42% (2003-2007)^{1,3} and 22-29% (2009-2015),^{4,5} probably due to earlier diagnosis and the introduction of more effective and/or less toxic antifungal drugs such as voriconazole, which is clinically available since 2002.⁶ Voriconazole and isavuconazole are the preferred first-line agents for the treatment of acute IA,⁷ but an increasing number of reports of triazole-resistance in *A. fumigatus* threatens these treatment options.⁸ Most triazole-resistance associated mutations are located in the 14- α -demethylase enzyme (*Cyp51A* gene), which converts lanosterol to ergosterol, a key component of fungal cell membrane.⁹ Triazole antifungals bind and block the function of this enzyme leading to membrane instability and subsequent fungal cell death.¹⁰ The most commonly reported resistance mechanisms among IA in haematology patients are the environmental associated mutations TR₃₄/L98H and TR₄₆/Y121F/T289A. The TR₃₄/L98H mutation typically confers panazole-resistance whereas the TR₄₆/Y121F/T289A mutation is associated with high voriconazole MICs while itraconazole and posaconazole MICs are variable.¹¹⁻¹³

Triazole-resistance prevalence in *A. fumigatus* varies between 3.2% to 36.3% depending on country, centre, and underlying condition (e.g. cystic fibrosis is associated with higher triazole resistance prevalence).^{12,14-20} Because *Aspergillus* does not grow from culture in >50% of cases,²¹ molecular methods are being developed to detect triazole-resistance directly in patient samples, but sensitivity variabilities of these assays is an issue.²² The impact of triazole-resistance on mortality is not completely known but rates as high as 50% – 100% have been reported in case-series of haematology patients with triazole-resistant IA.^{15,17,23,24} Since exposure to triazole-resistant conidia in the environment renders every patient at risk for developing triazole-resistant *Aspergillus* disease, an international expert panel recommended that in case of >10% triazole-resistance, primary treatment should be shifted away from triazole monotherapy to liposomal amphotericin B, or triazole and echinocandin combination therapy²⁵. As the initial therapy for IA in haematology patients should carefully balance resistance prevalence

versus efficacy, there is concern that shifting away from voriconazole/isavuconazole therapy may come at the expense of overall treatment efficacy. Therefore, another approach that has been advocated is the one in which a triazole constitutes part of the initial antifungal therapy until resistance is adequately documented by culture (or PCR).^{26,27} To assess the prevalence and mortality of voriconazole-resistant *A. fumigatus* IA, we performed a retrospective multicentre study in a large cohort of haematology patients with IA.

Patients and Methods

Study design and patient cohort

We retrospectively studied the prevalence and outcome of IA due to voriconazole-resistant *A. fumigatus* in patients with haematological malignancies in four University Medical Centres between 2012 and 2017 namely The University Hospitals Leuven in Belgium, the Radboud University Medical Centre (Nijmegen), Leiden University Medical Centre (Leiden) and Erasmus University Medical Centre (Rotterdam) in the Netherlands). Haematology patients diagnosed with probable or proven IA according to the 2008 consensus criteria of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections cooperative Group and The National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORCT/MSG)²⁸ with a positive *A. fumigatus* culture were included. Patients were further stratified by fungal susceptibility phenotype into voriconazole-susceptible and voriconazole-resistant cases.

Data collection

Cases of IA at the University Hospitals Leuven were retrieved through two registered studies (ClinicalTrials.gov NCT01176071 and NCT03004092), previously approved by the local Ethics Committee. Briefly, electronic files from adult patients (>18 years old) with a haematological disease diagnosed between 2012 and 2016 (NCT01176071) with a positive galactomannan test (see supplementary data section) or a positive culture for *A. fumigatus* were reviewed for the presence of IA. For 2017, haematology patients were prospectively screened for IA (NCT03004092). Only cases of

132 proven or probable IA from either trial with a positive *A. fumigatus* culture were included for further
133 analysis. Data from the Dutch centres had been previously collected as part of a multicentre retrospective
134 cohort study on IA regardless of the underlying disease.²⁹ The hospital wide cohort included all patients
135 with culture-positive IA,²⁹ but for the current study only haematology patients with proven or probable
136 IA were included for further analysis (94 out of 196 patients). Data was processed in accordance with
137 the Dutch Personal Data protection and did not fall under the Dutch law on research on human subjects.
138 In all centres, the antifungal care pathway included a diagnostic-driven approach. Positive serum
139 galactomannan (see supplementary data section), persistent (neutropenic) fever despite broad-spectrum
140 antibiotics, or clinical signs or symptoms suggestive of IA were triggers for performing a chest CT scan,
141 which was followed by bronchoalveolar lavage (BAL) with fungal culture and determination of
142 galactomannan on BAL fluid whenever patients presented with suspected lesions on the CT scan. When
143 clinically indicated, additional fungal cultures besides BAL were taken (sputum, bronchial aspirate,
144 biopsy, etc.).

145
146 Day zero was defined as the day on which mould-active antifungal therapy was started. Patients were
147 included in the intensive care unit (ICU) subgroup if antifungal therapy was initiated at the ICU, and if
148 the duration of admission at the ICU was at least two consecutive days. Survival was recorded at 6 and
149 12 weeks. Mycological data obtained included cultures performed, triazole-resistance screening,
150 susceptibility testing and resistance mutation determination in the *Cyp51A* gene of triazole-resistant
151 isolates. For comparison between voriconazole-susceptible and -resistant patients, we considered any
152 case with at least one resistant isolate as a voriconazole-resistant case (MIC > 2 mg/L). Isolates with an
153 intermediate susceptibility to voriconazole were considered as susceptible cases for this analysis (MIC
154 ≤ 2 mg/L). Appropriateness of initial antifungal therapy and switch of therapy were determined as well.
155 Initial antifungal therapy was considered as appropriate when a voriconazole-susceptible case received
156 a triazole antifungal as initial therapy. Initial antifungal therapy was considered inappropriate when a
157 voriconazole-resistant case started antifungal treatment with a triazole antifungal
158 (voriconazole/isavuconazole as study medication).

Mycology

All *A. fumigatus* positive cultures from haematological patients underwent comprehensive mycological analysis, including strain identification through macro- and micro-morphological visual inspection, species confirmation by either growth at 48°C or sequencing of the *β-tubulin* gene as previously described,³⁰ susceptibility testing and molecular determination of resistance mutations in the *Cyp51A* gene. MICs of itraconazole, voriconazole, posaconazole and amphotericin B were determined using the EUCAST broth microdilution reference method for filamentous fungi; resistance was established based on the EUCAST clinical breakpoints for *A. fumigatus*.³¹ In the Dutch centres, triazole-resistance screening was routinely performed for all *A. fumigatus* isolates using the commercially available 4-well agar plate dilution method VIPCheck® (MediaProducts, Groningen, The Netherlands), according to the manufacturer's recommendations. Briefly, all *Aspergillus* colonies that grew were swabbed to prepare a suspension (0.5 McFarland standard) in sterile water, of which 25µl was placed in each well and incubated at 36°C. Growth was recorded at 24 and 48 hours. Growth on any of the triazole (itraconazole, voriconazole, posaconazole) containing agars prompted MIC determination (EUCAST). The same routine triazole-resistance screening was introduced in the University Hospitals Leuven in 2015. Between 2012 and 2015, positive *A. fumigatus* cultures from haematological patients were directly subjected to susceptibility testing. The presence of mutations within the *Cyp51A* gene and its promotor region was assessed as described previously.^{32,33}

Statistical analysis

Fisher's exact test was used to compare categorical variables. The Mann-Whitney U test was used to compare continuous variables. Primary endpoints were survival at week 6 (42 days) and week 12 (84 days). Impact of voriconazole-susceptibility on survival was assessed using Kaplan-Meier estimators, and survival curves were compared using the log-rank test. We performed multivariate cox regression analysis on 12-week survival by resistance, controlling for ICU admission, EORCT/MSG proven or probable IA group, gender, age and triazole antifungal initial-therapy. All analyses were performed using R v3.4.4 (R Foundation for Statistical Computing, Vienna, Austria).

Results

We identified 129 *A. fumigatus* culture-positive proven or probable IA cases including voriconazole-susceptible (79.8%) and 26 voriconazole-resistant (20.2%) cases. Prevalences of voriconazole-resistance per centre were: University Hospitals Leuven 17.1% (6/35 cases), Radboud University Medical Centre 10.5% (2/19 cases), Leiden University Medical Centre 34.5% (10/29 cases) and Erasmus University Medical Centre 17.4% (8/46 cases). The patients' baseline characteristics are summarized in Table 1. No gender or age differences were observed between susceptible and resistant cases. The distribution of probable and proven IA classification did not vary between groups ($p = 1.00$). Initiation of antifungal therapy in the ICU represented approximately 15% of the cases in both groups, 15/103 cases in the susceptible and 4/26 cases in the voriconazole-resistant group ($p = 1.00$). No significant difference in voriconazole-resistance prevalence was observed in the ICU group (21%) compared to the non-ICU group (17.1%). Initial therapy consisted of triazole monotherapy in 75.2% (97/129) of patients; 77% (79/103) in voriconazole-susceptible IA and 69% (18/26) in voriconazole-resistant cases. Triazole antifungal therapy was mostly initiated in the non-ICU population (79%, 87/110 cases) with respect to the ICU population (52.6%, 10/19 cases). In the voriconazole-resistant IA group, 13 patients (72%) that started voriconazole monotherapy were switched to L-AmB, with a median time to switch of 11 days after start of triazole therapy [IQR 7.5-26]. None of the cases modified initial triazole treatment to a combination therapy. Among all cases, L-AmB or echinocandin therapy with or without combination with a triazole antifungal was initiated in 25% (32/129) of the patients; 24 cases among voriconazole-susceptible IA cases (23.3%) and 8 cases among voriconazole-resistant IA cases (30.8%). L-AmB was started more frequently in ICU patients (36.8%, 7/19 cases) compared to non-ICU patients (12.8%, 14/110 cases). Due to the retrospective design of our study, the reason for initial or switch of initial antifungal therapy was not available for the majority of the cases. Detailed information on the microbiological and clinical characteristics of voriconazole-resistant *A. fumigatus* culture-positive IA haematological patients is shown in Table 2. The majority of voriconazole-resistant isolates originated from BAL cultures (46.2%), followed by sputum cultures (34.6%). A pan-triazole resistance phenotype was observed in 77% (20/26) of the voriconazole-resistant isolates. Environment

associated resistance mutations in the *Cyp51A* gene were the most common reported mutations, TR₃₄/L98H (13/26, 50%) and TR₄₆/Y121F/T289A (12/26, 46.1%) of which one patient had mixed resistant TR₄₆/Y121F/T289A+ TR₃₄/L98H infection (patient 6); no mutations were found in the *Cyp51A* gene in one isolate (3.8%). All voriconazole-resistant *A. fumigatus* isolates tested were susceptible to amphotericin B (MIC $\leq$ 1 mg/L).

Within the voriconazole-resistant group, three patients presented with a mixed susceptible/resistant *A. fumigatus* infection, two with an initial resistant and susceptible isolate (patients 8, 9) and one with an initial susceptible isolate (patient 23). In the latter, the resistant isolate was cultured 6 days after the susceptible isolate (day 0) while on voriconazole treatment. Patient 22 had two independent episodes of IA, a triazole-susceptible and a triazole-resistant episode. Initially, the patient was diagnosed with a susceptible *A. fumigatus* isolate for which voriconazole treatment was initiated with a favourable clinical and mycological response. By day 4 of treatment, total neutrophil counts recovered (>500 neutrophils). By day 49, the patient received a second stem cell donation as treatment for marrow failure. By day 59 while on voriconazole treatment, a breakthrough IA infection was diagnosed due to triazole-resistant *A. fumigatus* and the patient died 22 days after diagnosis of triazole-resistant IA.

Mortality. All-cause mortality among the 129 haematological patients was 31% (40/129) at week 6 and 41.1% (53/129) at week 12. Mortality stratified by voriconazole-susceptibility in the overall, ICU and non-ICU population at weeks 6 and 12 is shown in Table 3. In the overall population, we observed a higher but non-significantly different all-cause mortality in the voriconazole-resistant group (42.3%, 11/26 cases) compared to the voriconazole-susceptible group (28.2%, 29/103 cases; $p = 0.200$) at week 6 and at week 12 (57.7%, 15/26 cases versus 36.9%, 38/103 cases; $p = 0.064$, Figure 1A). In the non-ICU population, mortality was significantly higher among resistant cases (54.5%, 12/22 cases) compared to susceptible ones (30.7%, 27/88 cases) at 12 weeks (24% mortality difference between groups, $p = 0.035$, Figure 1B). Mortality was highest in the ICU group with no significant difference in mortality in case of voriconazole resistance both at week 6 and week 12, which may be partially explained by the already very high mortality of 73% in the triazole susceptible ICU patient group.

Mortality based on appropriate initial triazole therapy (susceptible cases) or inappropriate initial triazole therapy (resistant cases), showed no significant differences in mortality at 12 weeks in overall cases, 38% (30/79 cases) versus 44.4% (8/18 cases, $p = 0.609$) respectively. No significant differences in mortality were observed as well in the non-ICU population when comparing appropriate initial therapy (33.3%, 23/69 cases) and inappropriate initial therapy (40%, 6/15 cases) at 12 weeks ($p=0.637$). Among the triazole-resistant cases, 12- week mortality in patients that switched from initial triazole-monotherapy to L-AmB was 46.2% (6/13 cases) compared to 40 % in patients whose initial triazole therapy was not modified (2/5 cases, $p = 0.785$). A trend indicating a decreased survival in patients with voriconazole-resistant IA infection was observed by multivariate cox regression analysis after controlling for possible confounders as ICU admission, EORCT/MSG proven or probable IA group, gender, age and triazole antifungal initial-therapy at 12 weeks (hazard ratio 1.74, $p = 0.072$; Table S1). Increased hazard risk ratios were observed for ICU patients (4.00, $p= 0.001$) and proven IA patients (2.37, $p = 0.007$) at 12 weeks.

Discussion

This study revealed a prevalence of 20.2% (26/103 cases) of voriconazole-resistant *A. fumigatus* among culture-positive IA in haematology patients, which varied between centres from 10 to 34%, and an associated increased mortality in non-ICU patients.

The prevalence of triazole resistance corresponds to previous reports from the Netherlands and the United States where resistance among culture-positive IA in haematology patients was 16.7% (2/12 cases)¹⁴ and 19.2% (11/52 cases),¹⁶ respectively. However, even higher prevalence of resistance of 30.3% (10/33 ICU cases)²³ and 36.3% (12/33 haematology cases)¹⁸ have been described by other centres. One German study found a resistance prevalence of 29.6% (8/27 cases) in autologous and allogenic stem cell transplant recipients.¹⁵ However, total numbers of IA cases in these studies were low, and because small changes in the number of triazole resistant cases significantly impact calculated prevalences,³⁴ multicentre studies are warranted to reliably estimate resistance prevalence. Moreover, the underlying mechanisms that lead to triazole resistance as well as its impact on MICs differs by region. In Europe, triazole resistance is almost entirely driven by *Cyp51A* gene mutations while other mechanisms seem to be involved in the study from the United States.¹⁶ Recently, a multicentre study in the Netherlands found a prevalence of voriconazole-resistance of 19% (37/196) among *A. fumigatus* culture-positive proven, probable or putative IA patients,²⁹ with 53% of the cases having an underlying haematological disease. The resistance prevalence for the Belgian centre (University Hospitals of Leuven, 17.1%) in this study was considerably higher than the 5.5% (9/164 cases) detected during a nationwide Belgian surveillance study (April 2011 - April 2012) which targeted all patients with *Aspergillus* disease. Only one single haematology patient with voriconazole-resistant IA was detected during that one-year survey conducted in 30 hospitals (4%, 1/25 cases).³³

In non-ICU patients with voriconazole-resistant IA, we observed a significantly higher 12-week mortality (54.5%) compared to voriconazole-susceptible cases (30.7%). This is in contrast with the US study in haematology patients in which no correlation between the MIC and the outcome of aspergillosis at week 6 was found. In the US study however, no high level triazole resistance was detected among their resistant cases (MIC $\geq$ 8 mg/L against any of the triazoles tested)¹⁶ and no *Cyp51A* gene resistance

associated mutations were documented. In addition, combination therapy was frequently used in the above mentioned cohort, which was not further detailed in the publication,¹⁶ but may also have contributed to the lack of correlation between resistance and outcome. In a Dutch multicentre cohort study with an intensive resistance screening and MIC-testing setting and a resistance prevalence of 19%, voriconazole-resistance was associated with an absolute increase in overall mortality of 21% on day 42 and 25% on day 90.²⁹ The 12-week all-cause mortality rate (57.7%) among haematology patients with voriconazole-resistant IA in our study is at the lower end of mortality rates reported by other non-comparative case series, which vary between 50% and 100%.^{12,15,23} In agreement with previous studies,^{23,29} we observed the highest 12-week mortality in the ICU-subgroup regardless of triazole susceptibility, which is a known confounder for mortality²⁹. L-AmB antifungal therapy was started more often in ICU patients compared to non-ICU patients (42% and 12.8% respectively; $p = 0.012$), however due to the retrospective nature of the study, the reason for this is not known. We could not find any significant differences in mortality in the ICU subgroup according to triazole susceptibility, which may be partially explained by the already very high mortality of 73.3% in the triazole susceptible ICU patient group, but also because of the severity of the patients underlying conditions and the small sample size. We did not observe any significant differences when comparing susceptible and resistant groups' characteristics (table 1). Even after controlling for possible confounders like ICU management, a trend indicating a decrease in survival in patients with voriconazole-resistant IA infection remains (hazard ratio 1.74, $p = 0.072$; Table S1).

In the recent hospital-wide cohort study from the Netherlands, mortality in patients who received appropriate initial voriconazole therapy was 24% compared with 47% in those who received inappropriate therapy, despite switching to appropriate antifungal therapy after a median of ten days.²⁹ We, however did not observe significant differences in mortality among overall and non-ICU haematology patients who received initial inappropriate (44.4% and 40%), appropriate (38% and 33.3%) triazole therapy or after voriconazole-resistant cases switched to an appropriate treatment with L-AmB (median time of 11 days). Several hypotheses can be raised that may contribute to this finding. First of all, the subgroup with initial inappropriate therapy, especially when focusing to the non-ICU population is very small ($n=15$) and does not allow to reliably perform this subanalysis. Secondly, it is possible that

more confounding factors play a role in the haematology invasive aspergillosis patient population compared to non-haematology invasive aspergillosis patient population. For instance, it is well known that neutrophil recovery as well as refractory haematological disease are important factors influencing the outcome of invasive fungal disease. On the other hand, our relatively small difference in survival between groups suggests a trend towards increased mortality in patients that received inappropriate initial triazole therapy, yet it may also indicate that initial triazole therapy does not negatively impact the outcome compared with immediate appropriate therapy even in regions with high resistance rates. However, as indicated previously, the number of patients with triazole-resistance according to the initial antifungal therapy becomes very small and it is not possible to draw any definite conclusions now. Moreover, several patients were part of clinical trials in whom initial therapy was modified within the first 48 hours after been assigned to study medication group, which is a limitation of our study.

Recently, a panel of 21 international experts proposed that regions with a high level of triazole-resistance (>10% prevalence in environmental isolates) should consider shifting initial treatment of IA from voriconazole monotherapy to either a combination of voriconazole plus an echinocandin or L-AmB,²⁵ which was also recommended in the recent ESCMID-ECMM-ERS *Aspergillus* guideline (The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society).³⁵ Given that national resistance surveillance of clinical *A. fumigatus* isolates in the Netherlands indicated that the 10% threshold has been reached for 3 consecutive years the Dutch Working Party on Antibiotic Policy (SWAB) recently recommended first line combination therapy for patients with IA, at least until triazole-susceptibility has been established.²⁶ Initial triazole therapy may be considered for the non-critically ill haematological patient only when early bronchoscopy together with immediate PCR-based testing for the presence of *Cyp51A* gene mutations is available.²⁶

Resistance prevalence data should however be interpreted with caution since the prevalence is dependent on the denominator used.³⁴ The resistance frequency in culture-positive cases might overestimate the true prevalence in the overall IA population, as most IA cases are culture-negative and thus phenotypic resistance assessment cannot be performed. The culture-positive cases may therefore be a specific subpopulation of patients with IA and the cases with highest fungal burden with a different

resistance prevalence and mortality compared to non-culture positive cases. Molecular methods may be helpful to detect triazole resistance directly in clinical samples and help to determine resistance prevalence in culture negative cases.²⁴ Montesinos *et al.* evaluated the resistance prevalence in IA patients by comparing two screening strategies, PCR (AsperGenius, PathoNostics, Maastricht, the Netherlands) versus culture-based strategy, but did not find any difference (prevalence 11.7% versus 10.5%)³⁶ suggesting that the resistance frequency found in culture may be extrapolated to the entire group of IA cases.

As survival of patients with an azole-susceptible IA treated with voriconazole or combination of voriconazole and an echinocandin is superior to L-AmB or echinocandin monotherapy,^{37–39} abandoning voriconazole as the initial treatment of choice might be counterproductive, jeopardizing the outcome in non-resistant cases. On the other hand, the increase in 12-week mortality and the high prevalence in patients with a culture-positive voriconazole-resistant IA in both the Dutch hospital-wide cohort²⁹ and in our cohort of haematology patients suggests that adaptations of voriconazole as the initial antifungal therapy should be considered, at least in triazole-resistant cases. Early detection of resistance seems critical to retain early triazole therapy and prevent excess mortality which is the topic of the ongoing the Azole-Resistance MANagement Study (AzoRMan, NCT03121235).²⁷ According to the study protocol, voriconazole is initiated in patients in whom IA is suspected. Treatment is re-evaluated following results obtained by prompt azole resistance testing results obtained by multiplex real-time PCR performed directly on BAL (AsperGenius). If resistance mutations are detected in the BAL sample the treating physician is advised to switch to L-AmB or, if PCR results are inconclusive to add a second antifungal.³⁴ This trial may provide evidence that supports retaining voriconazole monotherapy in a setting with > 10% environmental resistance, on the condition that a diagnostic strategy that enables early resistance detection is in place.

In conclusion, we found a high prevalence of voriconazole-resistant *A. fumigatus* in culture-positive IA in haematology patients in this multicentre study, with an increased mortality in voriconazole-resistant cases in non-ICU patients. Whether the use of voriconazole as initial antifungal therapy for the treatment of IA can be retained or not still needs further investigation.

367

368 **Acknowledgements**

369 We thank all the personnel from our centres involved in the diagnosis and treatment of our haematology
370 patients.

371

372 **Funding**

373 This study was carried out within our routine activities; no extra funding was needed.

374

375 **Transparency declarations**

376 The study was designed by K.L., J.M., P.P.L., P.E.V., A.R.S. and T.M. Data was collected and analysed
377 by P.P.L., T.M., A.F.A.D.S. and A.R.S. First draft of the manuscript was created by A.R.S. and T.M.
378 The final version of the manuscript was critically revised and adapted by A.R.S., T.M., P.P.L., J.M.,
379 B.J.A.R., A.F.A.D.S., M.T.B., J.J.C., E.K., P.V.D.B., P.E.V. and K.L.

380

381 **Transparency declarations:**

382 KL has received research grants, travel support and lecture honoraria from Gilead, MSD and Pfizer. She
383 participated in advisory boards for MSD and Gilead. T.M. has received lecture honoraria from Gilead
384 and non-financial support from MSD, OLM Diagnostics, IMMY and Gilead. J.M. has received research
385 grants, travel support and lecture honoraria from Gilead, MSD, Basilea Pharmaceuticals, Astellas, and
386 Pfizer and has participated in advisory boards for MSD, Gilead, Astellas, Basilea, Pfizer, F2G, Amplyx,
387 Scynexis and Cidara. B.J.A.R. reports grants from MSD and Gilead and personal fees from Gilead and
388 Great Lake pharmaceuticals. A.F.A.D.S. received travel grants from Abvie, Amgen, Roche and Gilead
389 to attend international conferences, not related to this manuscript. P.E.V. received research grants from
390 Gilead Sciences, Astellas, MSD, F2G, and Bio-Rad. He is a speaker for Gilead Sciences and MSD, and
391 is on the advisory boards for Pfizer, MSD, and F2G. The remaining authors have none to declare. Not
392 any of the mentioned work is related to this manuscript.

Tables

Table 1. - Characteristics of haematology patients with culture-positive invasive aspergillosis, comparing voriconazole-susceptible and voriconazole-resistant cases.

	Susceptible (n=103)	Resistant (n=26)	p	test
Male gender (%)	62 (60.2)	16 (61.5)	1.000	Fisher's exact
Age (median [IQR])	61.0 [46.5, 66.5]	58.5 [51.0, 64.0]	0.611	Mann-Whitney U
EORCT/MSG proven IA (%)	21 (20.4)	5 (19.2)	1.000	Fisher's exact
Treatment (%)			0.628	Fisher's exact
L-AmB	15 (14.6)	6 (23.1)		
Echinocandin	4 (3.9)	2 (7.7)		
Triazole (voriconazole + blinded clinical study ¹)	79 (76.7)	18 (69.2)		
Voriconazole + L-AmB	3 (2.9)	0 (0.0)		
Voriconazole + intrathecal caspofungin/L-AmB	1 (1.0)	0 (0.0)		
Voriconazole + echinocandin	1 (1.0)	0 (0.0)		
ICU subgroup (%) ²	15 (14.6)	4 (15.4)	1.000	Fisher's exact

¹ Randomized double-blinded clinical trial (voriconazole versus isavuconazole, voriconazole versus posaconazole)

² Initiation of antifungal therapy in the ICU and stay in the ICU for at least two consecutive days

Abbreviations: IA (invasive aspergillosis), EORCT/MSG (European Organization for Research and Treatment of Cancer/Invasive Fungal Infections cooperative group and the National Institute of Allergy and Infectious Diseases Mycoses study group consensus group definitions).

Table 2. Clinical characteristics of voriconazole-resistant *A. fumigatus* culture-positive invasive aspergillosis haematology patients

Patient	Centre	Gender	Age	Underlying disease	EORTC/MSG classification ¹	ICU ²	Sample origin	<i>Cyp51A</i> gene resistance mutation	MIC (mg/L)			Initial antifungal therapy	Antifungal therapy modification	Outcome week 6 (day 42)	Outcome week 12 (day 84)
									ITZ	VCZ	POS				
1	1	male	55	AlloSCT (AML)	probable	no	Sputum	WT	1	4	0,25	L-AmB	no	Alive	Dead (+52)
2	1	female	59	NHL	proven	no	Sinus biopsy	TR ₃₄ /L98H	>16	4	0,5	L-AmB	no	Dead (+15)	
3	2	female	69	MDS	probable	yes	BAL	TR ₄₆ /Y121F/T289A	>16	>16	1	L-AmB	voriconazole	Alive	Alive
4	2	male	51	NHL	probable	no	Sputum	TR ₃₄ /L98H	>16	8	0,5	voriconazole	L-AmB	Alive	Alive
5	2	female	64	NHL	probable	yes	BAL	TR ₄₆ /Y121F/T289A	>16	>16	1	voriconazole	L-AmB	Dead (+25)	
6	2	male	61	NHL	probable	no	Sputum	TR ₃₄ /L98H + TR ₄₆ /Y121F/T289A	>16	>16	1	L-AmB	no	Dead (+11)	
7	2	female	19	NHL	probable	no	Sputum	TR ₃₄ /L98H	>16	8	1	voriconazole	no	Dead (+18)	
8	2	male	54	NHL	probable	no	BAL	TR ₃₄ /L98H	>16	8	1	voriconazole	L-AmB	Alive	Alive
9	2	male	45	NHL	probable	no	Bronchial aspirate	TR ₄₆ /Y121F/T289A	1	>16	0,25	voriconazole	L-AmB	Alive	Alive
10	2	female	67	AML	probable	no	Bronchial aspirate	TR ₄₆ /Y121F/T289A	>16	>16	0,25	voriconazole	L-AmB	Alive	Alive
11	2	male	62	AlloSCT (NHL)	probable	no	Tissue biopsy	TR ₄₆ /Y121F/T289A	0,5	>16	0,5	voriconazole	L-AmB	Alive	Alive
12	2	male	70	AML	probable	yes	Bronchial aspirate	TR ₃₄ /L98H	>16	8	1	voriconazole	L-AmB	Alive	Alive
13	3	male	46	NHL	probable	no	BAL	TR ₃₄ /L98H	>16	4	0,5	voriconazole	no	Alive	Alive
14	3	male	29	AlloSCT (HL)	probable	yes	BAL	TR ₃₄ /L98H	>16	8	2	voriconazole	no	Alive	Dead (+44)
15	3	male	64	Haematological malignancy	probable	no	BAL	TR ₄₆ /Y121F/T289A	>16	4	1	voriconazole	no	Alive	Alive
16	3	male	22	AlloSCT	probable	no	Sputum	TR ₄₆ /Y121F/T289A	>16	>16	1	L-AmB	no	Dead (+9)	
17	3	female	62	Haematological malignancy	proven	no	BAL	TR ₄₆ /Y121F/T289A	2	>16	1	voriconazole	L-AmB	Dead (+10)	
18	3	female	40	AlloSCT	proven	yes	BAL	TR ₃₄ /L98H	>16	4	1	voriconazole	voriconazole + echinocandin	Dead (+32)	
19	3	male	53	Haematological malignancy	probable	no	Sputum	TR ₄₆ /Y121F/T289A	>16	>16	1	voriconazole	L-AmB	Alive	Dead (+66)
20	3	female	64	Haematological malignancy	probable	no	Sputum	TR ₃₄ /L98H	>16	16	2	voriconazole	no	Alive	Alive
21	4	Male	75	ALL	Probable	no	BAL	TR ₃₄ /L98H	>16	4	1	L-AmB	no	Dead (+3)	
22	4	Male	51	AutoSCT (HL)	Proven	no	Sputum	TR ₄₆ /Y121F/T289A	>16	>16	1	voriconazole + echinocandin	L-AmB	Dead (+22)	
23	4	Female	69	AlloSCT (AML)	Probable	yes	BAL	TR ₃₄ /L98H	>16	8	1	voriconazole	L-AmB	Dead (+11)	
24	4	Male	58	AML	Probable	no	BAL	TR ₃₄ /L98H	>16	4	1	echinocandin	L-AmB + echinocandin	Alive	Dead (+66)
25	4	Female	62	NHL	Probable	yes	Sputum	TR ₃₄ /L98H	8	2	1	voriconazole	L-AmB	Alive	Alive
26	4	Male	57	AlloSCT (MM)	Proven	no	BAL	TR ₄₆ /Y121F/T289A	4	>8	1	triazole ³	L-AmB	Dead (+19)	

1. Invasive aspergillosis classification according to the Modified EORTC/MSG criteria (European Organization for Research and Treatment of Cancer/Invasive Fungal Infections cooperative group and the National Institute of Allergy and Infectious Diseases Mycoses study group consensus group definitions).
2. ICU: Initiation of antifungal therapy in the ICU and stay in the ICU for at least two consecutive days
3. Patient included in a randomized double-blinded clinical trial (voriconazole versus isavuconazole)

Abbreviations: MIC (minimal inhibitory concentration), ALL (acute lymphoblastic leukaemia), AutoSCT (autologous stem cell transplant), AlloSCT (allogenic stem cell transplant), HL (Hodgkin lymphoma), AML (acute myeloid leukaemia), NHL (non-Hodgkin lymphoma), MM (multiple myeloma), MDS (myelodysplastic syndrome), BAL (bronchoalveolar lavage), WT (Wild type phenotype), L-AmB (liposomal amphotericin B), ITZ (itraconazole), VCZ (voriconazole), POS (posaconazole).

Table 3. Comparison of all-cause mortality in culture-positive invasive aspergillosis haematology patients according to voriconazole susceptibility

Outcome: Dead		Number	%	P
Week 6 (42 days)				
	Overall			0.200
	Susceptible	29/103	28.2	
	Resistant	11/26	42.3	
	ICU			0.900
	Susceptible	10/15	66.7	
	Resistant	3/4	75.0	
	Non-ICU			0.160
	Susceptible	19/88	21.6	
	Resistant	8/22	36.4	
Week 12 (84 days)				
	Overall			0.064
	Susceptible	38/103	36.9	
	Resistant	15/26	57.7	
	ICU			0.990
	Susceptible	11/15	73.3	
	Resistant	3/4	75.0	
	Non-ICU			0.035
	Susceptible	27/88	30.7	
	Resistant	12/22	54.5	

Figure legends

Figure 1. Overall survival of haematology patients with voriconazole-resistant and voriconazole-susceptible invasive aspergillosis (IA) at 12 weeks (day 84). **A.** Survival curve of all IA haematology patients. **B.** Survival curve of IA haematology patients that did not start antifungal therapy at the ICU. Solid lines represent patients with voriconazole-susceptible isolates. Dotted lines represent patients with voriconazole-resistant isolates.

Figure 1A.

Figure 1B.

References

1. Pagano L, Caira M, Candoni A, *et al.* The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. *Haematologica*. 2006;**91**:1068-1075.
2. Lin S-J, Schranz J, Teutsch SM. Aspergillosis Case-Fatality Rate: Systematic Review of the Literature. *Clin Infect Dis*. 2001;**32**:358-366. doi:10.1086/318483
3. Pagano L, Caira M, Picardi M, *et al.* Invasive Aspergillosis in Patients with Acute Leukemia: Update on Morbidity and Mortality—SEIFEM-C Report. *Clin Infect Dis*. 2007;**44**:1524-1525. <http://dx.doi.org/10.1086/517849>.
4. van de Peppel RJ, Visser LG, Dekkers OM, *et al.* The burden of Invasive Aspergillosis in patients with haematological malignancy: A meta-analysis and systematic review. *J Infect*. 2018;**76**:550-562. doi:10.1016/j.jinf.2018.02.012
5. Slobbe L, Polinder S, Doorduyn JK, *et al.* Outcome and Medical Costs of Patients with Invasive Aspergillosis and Acute Myelogenous Leukemia–Myelodysplastic Syndrome Treated with Intensive Chemotherapy: An Observational Study. *Clin Infect Dis*. 2008;**47**:1507-1512. doi:10.1086/591531
6. Verweij PE, Chowdhary A, Melchers WJG, *et al.* Azole resistance in aspergillus fumigatus: Can we retain the clinical use of mold-active antifungal azoles? Weinstein RA, ed. *Clin Infect Dis*. 2016;**62**:362-368. doi:10.1093/cid/civ885
7. Tissot F, Agrawal S, Pagano L, *et al.* ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. *Haematologica*. 2017;**102**:433-444. doi:10.3324/haematol.2016.152900
8. Lestrade PPA, Meis JF, Melchers WJG, *et al.* Triazole resistance in *Aspergillus fumigatus*: recent insights and challenges for patient management. *Clin Microbiol Infect* 2018: [Epub ahead of print]. doi:10.1016/j.cmi.2018.11.027
9. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, *et al.* A point mutation in the 14alpha-sterol demethylase gene *cyp51A* contributes to itraconazole resistance in *Aspergillus fumigatus*. *Antimicrob Agents Chemother*. 2003;**47**:1120-1124. doi:10.1128/AAC.47.3.1120-1124.2003
10. Xiao L, Madison V, Chau AS, *et al.* Three-Dimensional Models of Wild-Type and Mutated Forms

of Cytochrome P450 14 α -Sterol Demethylases from *Aspergillus fumigatus* and *Candida albicans* Provide Insights into Posaconazole Binding. *Antimicrob Agents Chemother.* 2004;**48**:568-574. doi:10.1128/AAC.48.2.568-574.2004

11. Snelders E, Van Der Lee HAL, Kuijpers J, *et al.* Emergence of azole resistance in *Aspergillus fumigatus* and spread of a single resistance mechanism. *PLoS Med.* 2008;**5**:1629-1637. doi:10.1371/journal.pmed.0050219
12. van der Linden JWM, Snelders E, Kampinga GA, *et al.* Clinical implications of azole resistance in *Aspergillus fumigatus*, The Netherlands, 2007-2009. *Emerg Infect Dis.* 2011;**17**:1846-1854. doi:10.3201/eid1710.110226
13. Van Der Linden JWMM, Camps SMTT, Kampinga GA, *et al.* Aspergillosis due to voriconazole highly resistant *Aspergillus fumigatus* and recovery of genetically related resistant isolates from domiciles. *Clin Infect Dis.* 2013;**57**:513-520. doi:10.1093/cid/cit320
14. Lestrade PP, van der Velden WJFM, Bouwman F, *et al.* Epidemiology of invasive aspergillosis and triazole-resistant *Aspergillus fumigatus* in patients with haematological malignancies: A single-centre retrospective cohort study. *J Antimicrob Chemother.* 2018;**73**:1389-1394. doi:10.1093/jac/dkx527
15. Steinmann J, Hamprecht A, Vehreschild MJ, *et al.* Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. *J Antimicrob Chemother.* 2014;**70**:1522-1526. doi:10.1093/jac/dku566
16. Heo ST, Tatara AM, Jiménez-Ortigosa C, *et al.* Changes in In Vitro Susceptibility Patterns of *Aspergillus* to Triazoles and Correlation with Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015. *Clin Infect Dis.* 2017;**65**:216-225. doi:10.1093/cid/cix297
17. Koehler P, Hamprecht A, Bader O, *et al.* Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. *Int J Antimicrob Agents.* 2017;**49**:218-223. doi:10.1016/j.ijantimicag.2016.10.019
18. Fuhren J, Voskuil WS, Boel CHE, *et al.* High prevalence of azole resistance in *Aspergillus fumigatus* isolates from high-risk patients. *J Antimicrob Chemother.* 2015;**70**:2894-2898. doi:10.1093/jac/dkv177

19. van der Linden JWM, Arendrup MC, Warris A, *et al.* Prospective multicenter international surveillance of azole resistance in *Aspergillus fumigatus*. *Emerg Infect Dis.* 2015;**21**:1041-1044. doi:10.3201/eid2106.140717
20. Engel TGP, Slabbers L, de Jong C, *et al.* Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients – A Dutch, multicentre study. *J Cyst Fibros.* 2019;**18**:221-226. doi:10.1016/j.jcf.2018.11.012
21. Nicolle M-C, Bénét T, Thiebaut A, *et al.* Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. *Haematologica.* 2011;**96**:1685-1691. doi:10.3324/haematol.2011.044636
22. Postina P, Skladny J, Boch T, *et al.* Comparison of Two Molecular Assays for Detection and Characterization of *Aspergillus fumigatus* Triazole Resistance and Cyp51A Mutations in Clinical Isolates and Primary Clinical Samples of Immunocompromised Patients. *Front Microbiol.* 2018;**9**:555. doi:10.3389/fmicb.2018.00555
23. van Paassen J, Russcher A, In 't Veld-van Wingerden AW, *et al.* Emerging aspergillosis by azole-resistant *Aspergillus fumigatus* at an intensive care unit in the Netherlands, 2010 to 2013. *Euro Surveill.* 2016;**21**:1-9. doi:10.2807/1560-7917.ES.2016.21.30.30300
24. Chong GM, van der Beek MT, von dem Borne PA, *et al.* PCR-based detection of *Aspergillus fumigatus* Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay[®] in 201 patients with haematological disease suspected for invasive aspergillosis. *J Antimicrob Chemother.* 2016;**71**:3528-3535. doi:10.1093/jac/dkw323
25. Verweij PE, Ananda-Rajah M, Andes D, *et al.* International expert opinion on the management of infection caused by azole-resistant *Aspergillus fumigatus*. *Drug Resist Updat.* 2015;**21-22**:30-40. doi:10.1016/j.drug.2015.08.001
26. SWAB Invasive Fungal Infections Guidelines Committee. Dutch Working Party on Antibiotic Policy. *SWAB Guideline XIII - Invasive fungal infections 2017.* 2017:1-66. [last accessed 13/05/2019]. [https://swabid.nl/sites/default/files/SWAB Richtlijn Mycosen 2017 %28final%29_compressed.pdf](https://swabid.nl/sites/default/files/SWAB_Richtlijn_Mycosen_2017_28final_29_compressed.pdf).

27. Schauwvlieghe AFAD, de Jonge N, van Dijk K, *et al.* The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol. *Mycoses*. 2018;**61**:656-664. doi:10.1111/myc.12788
28. De Pauw B, Walsh TJ, Donnelly JP, *et al.* Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. *Clin Infect Dis*. 2008;**46**:1813-1821. doi:10.1086/588660
29. Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD, *et al.* Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study. *Clin Infect Dis • CID*. 2018;**68**:1463-1471 . doi:10.1093/cid/ciy859
30. Snelders E, Karawajczyk A, Schaftenaar G, *et al.* Azole resistance profile of amino acid changes in *Aspergillus fumigatus* CYP51A based on protein homology modeling. *Antimicrob Agents Chemother*. 2010;**54**:2425-2430. doi:10.1128/AAC.01599-09
31. M.C. Arendrup, J. Guinea, M. Cuenca-Estrella, *et al.* EUCAST DEFINITIVE DOCUMENT E.DEF 9.3: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds version 9.3. *Eur Comm Antimicrob Susceptibility Test - EUCAST*. 2015;1-13.
32. Alanio A, Sitterlé E, Liance M, *et al.* Low prevalence of resistance to azoles in *Aspergillus fumigatus* in a French cohort of patients treated for haematological malignancies. *J Antimicrob Chemother*. 2011;**66**:371-374. doi:10.1093/jac/dkq450
33. Vermeulen E, Maertens J, De Bel A, *et al.* Nationwide surveillance of azole resistance in *Aspergillus* diseases. *Antimicrob Agents Chemother*. 2015;**59**:4569-4576. doi:10.1128/AAC.00233-15
34. Verweij PE, Lestrade PPA, Melchers WJG, *et al.* Azole resistance surveillance in *Aspergillus fumigatus*: beneficial or biased? *J Antimicrob Chemother*. 2016;**71**:2079-2082. doi:10.1093/jac/dkw259
35. Ullmann AJ, Aguado JM, Arikan-Akdagli S, *et al.* Diagnosis and management of *Aspergillus*

diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. *Clin Microbiol Infect.*

2018;**24**:e1-e38. doi:10.1016/J.CMI.2018.01.002

36. Montesinos I, Argudín MA, Hites M, *et al.* Culture-Based Methods and Molecular Tools for Azole-Resistant *Aspergillus fumigatus* Detection in a Belgian University Hospital. *J Clin Microbiol.* 2017;**55**:2391-2399. doi:10.1128/JCM.00520-17
37. Marr KA, Schlamm HT, Herbrecht R, *et al.* Combination Antifungal Therapy for Invasive Aspergillosis. *Ann Intern Med.* 2015;**162**:81-89. doi:10.7326/M13-2508
38. Herbrecht R, Denning DW, Patterson TF, *et al.* Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. *N Engl J Med.* 2002;**347**:408-415. doi:10.1056/NEJMoa020191
39. Viscoli C, Herbrecht R, Akan H, *et al.* An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. 2009;**64**:1274-1281. doi:10.1093/jac/dkp355

Supplementary data

Supplementary methods

Data collection

Cases of IA at the University Hospitals Leuven were retrieved through two registered studies (ClinicalTrials.gov NCT01176071 and NCT03004092), previously approved by the local Ethics Committee. Briefly, cases diagnosed between 2012 and 2016 (NCT01176071) were collected retrospectively. In this trial, electronic patient files of adult patients' ≥ 18 years with a haematological disease and a positive galactomannan test (optical density index ≥ 0.5 on two sequential serum samples or a single bronchoalveolar lavage sample with OD ≥ 0.5) or a positive culture for *A. fumigatus* were reviewed for the presence of IA. For 2017, cases were collected as part of the NCT03004092 trial, which prospectively screened haematology patients ≥ 18 years for IA. Only cases of proven or probable IA from either trial with a positive *A. fumigatus* culture were included for further analysis. Data from the Dutch centres had been previously collected as part of a multicentre retrospective cohort study on IA regardless of the underlying disease²⁶. Briefly, local microbiology databases were screened for positive *A. fumigatus* cultures of admitted patients. The hospital wide cohort included all patients with culture-positive IA²⁶, but for the current study only haematology patients with proven or probable IA were included for further analysis. Data was processed in accordance with the Dutch Personal Data protection and did not fall under the Dutch law on research on human subjects, as confirmed by the local Institutional Review Boards.

Diagnostic-driven approach

Galactomannan determination: Serum galactomannan was determined in haematology patients with either febrile neutropenia, >96 hours of fever despite use of broad spectrum antibiotics regardless of immune status or in haematology patients at high-risk of IA (i.e. receiving remission-induction or re-induction chemotherapy for acute myeloid leukaemia or myelodysplastic syndrome, patients receiving immunosuppressive therapy for aplastic anaemia or graft-versus-host disease, or allogeneic cell transplantation) with galactomannan measurements at least two times weekly (UZ Leuven, Radboud MC).

Table S1. Cox regression analysis on 12-week survival in culture-positive invasive aspergillosis haematology patients according to voriconazole resistance.

	Hazard risk ratio	95% CI	p value
Multivariate analysis at 12 weeks			
Voriconazole-resistance	1.744	0.951 - 3.196	0.072
ICU ¹	4.020	2.108 - 7.667	<0.001
Proven IA ²	2.374	1.268 - 4.446	0.007
Male	1.445	0.808 - 2.584	0.215
Initial triazole antifungal therapy	0.561	0.295 - 1.067	0.078
Age	1.021	1.003 - 1.039	0.025
Univariate analysis at 12 weeks			
Voriconazole-resistance	1.751	0.962 - 3.187	0.067

1. Intensive Care Unit (ICU): Initiation of antifungal therapy in the ICU and stay in the ICU for at least two consecutive days
2. Invasive aspergillosis classification according to the Modified EORCT/MSG criteria (European Organization for Research and Treatment of Cancer/Invasive Fungal Infections cooperative group and the National Institute of Allergy and Infectious Diseases Mycoses study group consensus group definitions).